BerGenBio ASA announced that it presented data linking AXL activation to STK11 loss of function in Non-Small Cell Lung Cancer in an abstract titled, AXL as a Therapeutic Target in STK11 mutant NSCLC, at the American Association for Cancer Research Annual Meeting 2023.
